CEL-SCI Co. (NYSEAMERICAN:CVM) saw a significant decrease in short interest in the month of October. As of October 31st, there was short interest totalling 583,301 shares, a decrease of 12.8% from the October 13th total of 668,765 shares. Based on an average daily trading volume, of 162,314 shares, the short-interest ratio is currently 3.6 days. Currently, 5.3% of the company’s stock are short sold.

A number of research firms have weighed in on CVM. Dawson James restated a “neutral” rating on shares of CEL-SCI in a report on Monday, October 16th. ValuEngine upgraded CEL-SCI from a “strong sell” rating to a “sell” rating in a report on Monday, August 14th.

Shares of CEL-SCI (NYSEAMERICAN CVM) traded up $0.14 on Monday, hitting $1.82. The stock had a trading volume of 338,400 shares, compared to its average volume of 176,218. CEL-SCI has a 12-month low of $1.46 and a 12-month high of $7.50.

In other CEL-SCI news, insider Eyal Talor sold 14,019 shares of the company’s stock in a transaction on Wednesday, August 16th. The stock was sold at an average price of $2.61, for a total transaction of $36,589.59. Following the completion of the sale, the insider now owns 131,312 shares in the company, valued at $342,724.32. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Vicente Benjamin Asuncion sold 160,000 shares of the company’s stock in a transaction on Tuesday, October 17th. The stock was sold at an average price of $0.39, for a total value of $62,400.00. In the last 90 days, insiders have sold 174,788 shares of company stock valued at $100,458.

TRADEMARK VIOLATION NOTICE: This story was originally reported by American Banking News and is the property of of American Banking News. If you are viewing this story on another website, it was illegally stolen and republished in violation of United States & international copyright law. The correct version of this story can be accessed at https://www.americanbankingnews.com/2017/11/13/cel-sci-co-cvm-short-interest-update.html.


CEL-SCI Corporation is engaged in the research and development at developing the treatment of cancer and other diseases by using the immune system. The Company is focused on activating the immune system to fight cancer and infectious diseases. It operates through the segment of research and development of certain drugs and vaccines.

Receive News & Ratings for CEL-SCI Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CEL-SCI Co. and related companies with MarketBeat.com's FREE daily email newsletter.